Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Filings indexed 679 across all filing types
Latest filing 2018-12-10 Board/Management Inform…
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated December 6, 2018. The content focuses on the appointment of a new director, Cynthia Collins, to the Board of Directors, and the resignation of another director, Boris Nikolic. It details the director's background, compensation, and indemnification agreement. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, this document should be classified as MANG with high confidence.
2018-12-10 English
FORM 3 -
Director's Dealing
2018-12-10 English
FORM 4 -
Director's Dealing
2018-12-06 English
FORM 4 -
Director's Dealing
2018-11-27 English
FORM 4 -
Director's Dealing
2018-11-21 English
10-Q
Interim / Quarterly Report 9M 2018
2018-11-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.